Tilray, Inc. (“
Tilray”) (NASDAQ | TSX: TLRY), a
global pioneer in cannabis research, cultivation, production, and
distribution, today announced that its medical subsidiary, Aphria,
has launched medical cannabis oral strips in THC and CBD-rich
varieties. Powered by QuickStrip’s™ proprietary technology, each
Aphria medical strip contains a thin, edible film that contains
rapidly dissolving, micronized cannabinoids that absorb directly
into the bloodstream, providing patients with a fast-acting,
convenient, and precise dosing experience for relief from a range
of conditions.
Irwin D. Simon, Tilray’s Chairman and Chief
Executive Officer, said, “Tilray’s medical brands, Aphria, Symbios,
and Tilray, are relentlessly committed to investing in patient
wellness through a portfolio of new innovative product offerings,
GMP-certified cultivation, and the earned trust of the medical
community. The launch of the Aphria-branded medical strips is a
compelling proof point in this regard, and, given the growing
expansion of medical cannabis across the globe, we believe we are
exceptionally well-positioned in this high-growth, high-margin
market moving forward. We look forward to extending our leadership
in medical cannabis and to delivering value for patients and
shareholders alike.”
Blair MacNeil, President at Tilray Canada,
added, “At Aphria Medical, our goal is to be the trusted partner
for patients by providing them with high-quality, precise, and
efficacious medical cannabis treatment. Delivering on this mission
means meeting patients ‘where they are,’ including those who are
unable or reluctant to swallow medication or do not prefer the
taste of cannabis oil. To address this need, Aphria has pioneered a
superior, non-combustible, discreet, and easy-to-use method of
consumption that utilizes micronized cannabinoids for rapid
absorption and relief from a range of conditions.”
The strips, which are now available throughout
Canada, are available in three different cannabis ratios: THC 10,
CBD 20:1, and THC:CBD 10:10 (coming soon). Each pack of Aphria oral
strips comes with 30 individually wrapped strips for precise,
single-dose delivery.
About Aphria Medical
Aphria Medical started in 2014 in Leamington,
Ontario, as one of the first companies to provide access to legal
medical cannabis. Since then, the Aphria brand has grown to be one
of the top medical cannabis providers globally, with operations in
Canada and international markets. Aphria remains committed to
supplying its growing patient base with safe, affordable,
consistent, and effective medical cannabis products.
For more information, visit: www.aphria.ca
About Tilray
Tilray, Inc. (Nasdaq: TLRY; TSX: TLRY) is a
leading global cannabis-lifestyle and consumer packaged goods
company with operations in Canada, the United States, Europe,
Australia, and Latin America that is changing people's lives for
the better – one person at a time – by inspiring and empowering the
worldwide community to live their very best life by providing them
with products that meet the needs of their mind, body, and soul and
invoke a sense of wellbeing. Tilray’s mission is to be the trusted
partner for its patients and consumers by providing them with a
cultivated experience and health and wellbeing through
high-quality, differentiated brands and innovative products. A
pioneer in cannabis research, cultivation, and distribution,
Tilray’s unprecedented production platform supports over 20 brands
in over 20 countries, including comprehensive cannabis offerings,
hemp-based foods, and alcoholic beverages.
For more information
about Tilray medical cannabis products,
visit: www.Tilray.caFor more information about Tilray, visit
www.Tilray.com
Forward-Looking Statements
Certain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the Company’s ability
to become the world's leading cannabis-focused consumer branded
company with our target of $4 billion of revenue by 2024; the
Company’s position and plans to be the #1 Canadian LP in total
sales on a consolidated basis; management’s projected growth in
market share and revenue in the EU cannabis market and its
Sweetwater and Manitoba Harvest businesses; and expectations
regarding the Company’s achievement of synergy targets. Many
factors could cause actual results, performance or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Tilray and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC)
of Tilray made with the SEC and available on EDGAR. The
forward-looking statements included in this communication are made
as of the date of this communication and the Company does not
undertake any obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
For media inquiries, please
contact: Jaydon Casenews@tilray.com
For investor inquiries please contact:Raphael
Gross203-682-8253Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024